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MicroAbstract 1 
Renal impairment (RI) is common in multiple myeloma (MM) and is associated with poor prognosis. 2 
The Australia and New Zealand Myeloma Registry was used to assess >1000 newly diagnosed MM 3 
patients, of whom 383 had RI at diagnosis. Patients who underwent autologous stem cell transplant 4 
(ASCT) despite RI had improved survival; potential factors for an inferior outcome include 5 
suboptimal use of bortezomib and ASCT. 6 
Abstract 7 
Background: Renal impairment (RI) is a common complication of multiple myeloma (MM) and 8 
remains a poor prognostic factor despite improved survival with newer therapies. 9 
Patients and Methods: We evaluated baseline characteristics, treatment and outcomes of newly 10 
diagnosed MM patients with RI at diagnosis in the Australia and New Zealand Myeloma and Related 11 
Diseases Registry over 5 years to April 2018; comparing RI patients (eGFR<60 ml/min) with eGFR≥60. 12 
In autologous stem cell transplant (ASCT) analyses, patients ≤70 years and ≥1 year from diagnosis 13 
were included. 14 
Results: Overall, 36% of newly diagnosed MM had RI; they were older, had more advanced disease 15 
and comorbidities, and worse performance status. Bortezomib-based induction therapy was most 16 
commonly used, although administered to fewer RI patients, despite similar response rates. Patients 17 
with RI were less likely to receive ASCT; however, recipients had longer progression-free (PFS) and 18 
overall survival (OS). Patients with RI had shorter OS and PFS after adjusting for age. In ASCT 19 
recipients with RI versus no RI, there was no difference in PFS and OS.  20 
Conclusion: Our findings in ‘real world’ MM patients with RI confirm that patient-, disease- and 21 
treatment-related factors (such as suboptimal bortezomib and ASCT use), and delays in commencing 22 
therapy, may contribute to poorer outcomes, and support the use of ASCT in patients with RI. 23 
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Introduction 1 
Renal impairment (RI) is a poor prognostic factor in multiple myeloma (MM). Despite improvements 2 
in survival with the introduction of novel therapies in recent years, RI remains one of the most 3 
common complications with an incidence of 20 to 50% at diagnosis, and approximately 5 to 10% of 4 
MM patients are dialysis-dependent.
1-3
 The most common cause of RI in MM is cast nephropathy, in 5 
which excess light chains form aggregates and casts resulting in tubular blockage and inflammation.
4-
6 
6
 Other factors include toxic effects of light chains on the basement membranes of glomeruli and 7 
proximal tubules, interstitial nephritis, amyloid deposition and plasma cell infiltration, which are 8 
further exacerbated by hypercalcaemia, dehydration, hyperuricaemia and nephrotoxic drugs. 9 
Recent developments including the significant efficacy of proteasome inhibitors (PI) in reversing 10 
renal failure, and the development of other new agents (such as monoclonal antibodies) are likely to 11 
improve disease outcome. The role of autologous stem cell transplant (ASCT) in the transplant-12 
eligible (TE) population with RI has not been definitively established. Current International Myeloma 13 
Working Group (IMWG) guidelines indicate level C evidence for ASCT at a reduced melphalan 14 
conditioning dose of 140 mg/m
2
; however some studies have demonstrated the feasibility and 15 
efficacy of full-dose conditioning,
7, 8
 despite others recommending dose reduction in some patients
7, 
16 
9
. The choice of induction agent(s) in both TE and non-TE patients also varies, and whether 17 
combination therapy provides incremental benefit in this high-risk group needs further clarification.  18 
With the overall improvement in prognosis in MM patients,
10
 it is crucial to evaluate whether there 19 
has been comparable progress in outcomes for this high-risk group with RI. In Australia and New 20 
Zealand, treatment protocols usually follow government reimbursement policy, for which 21 
combination novel therapies and maintenance therapy (other than thalidomide) are as yet 22 
unavailable outside of clinical trials. We investigated current treatment and clinical outcomes for 23 
MM patients with RI at diagnosis in Australia and New Zealand using a large, bi-national, real world, 24 
prospective clinical registry.  25 
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Methods 1 
Data sources 2 
Data for this study were obtained from the Australian and New Zealand Myeloma and Related 3 
Diseases Registry (ANZ MRDR). Details regarding the methods of the MRDR have been published 4 
separately,
11
 and it is registered on the Australian and New Zealand Clinical Trials Registry 5 
(ACTRN12618000659202). In brief, the MRDR is a prospective registry established in 2012, of newly 6 
diagnosed patients aged 18 years and older with MM, monoclonal gammopathy of undetermined 7 
significance (MGUS), smouldering MM, plasma cell leukaemia or solitary plasmacytoma identified by 8 
participating sites. The MRDR uses an opt-out consent model. Patient characteristics, co-morbidities, 9 
disease characteristics, laboratory parameters and first-line therapy are collected at baseline; then 10 
data on therapy, response, disease progression and other outcomes are collected every four months 11 
for MM patients and annually for MGUS patients. Periodic linkage is performed with the national 12 
death registries in Australia and New Zealand to ensure the quality of survival / mortality outcomes 13 
and to provide supplementary data on date and cause of death for any patients lost to follow up.  14 
Patients 15 
For this analysis we included all patients with newly diagnosed MM registered in the ANZ MRDR 16 
from 1 February 2013 to 24 April 2018.  17 
Definitions 18 
The Kidney Disease: Improving Global Outcomes (KDIGO) classification for chronic kidney disease
12
 19 
was used to classify renal function as recommended by the IMWG.
6
 The eGFR reported in the 20 
registry is generally derived from laboratory results using the CKD-EPI formula which has been 21 
recommended for use in Australasian laboratories since 2012.
13
 RI was defined as eGFR < 22 
60mL/min/1.73m
2
. Patient-, disease- and treatment-related factors were compared. Standard IMWG 23 
criteria for response were used.
14
 24 
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We classified transplant-eligible (TE) patients as those aged ≤ 70 years at diagnosis; the analyses only 1 
included patients with diagnosis date ≥ 1 year prior to data extraction (to allow time for transplant) 2 
and who had follow-up data.  3 
Statistical analysis 4 
Summary statistics are presented as proportion, mean (standard deviation) or median (inter-quartile 5 
range) as appropriate. Comparisons between groups were made using the Chi-square, Wilcoxon 6 
Rank sum, or Kruskal-Wallis test as appropriate. OS and PFS were calculated using Kaplan-Meier 7 
survival analysis, with censoring on death. The proportional hazards assumption was tested and all 8 
analyses were done using Stata version 15.1 (StataCorp LLC, Texas, USA). 9 
Results  10 
Patient and disease characteristics 11 
Of 1251 patients with MM on the MRDR, 1069 (85%) had eGFR available at diagnosis (Figure 1), and 12 
these 1069 patients were used in the RI analyses. Of these patients, 36% had RI (eGFR < 60 13 
mL/min/1.73m
2
): 24% had eGFR 30-59 mL/min; 6% had eGFR 15-29 mL/min; and eGFR was <15 14 
mL/min in 6% of patients.  15 
Compared with patients who had normal renal function, patients with RI at diagnosis were older (72 16 
v 65 years, p<0.001) and had more advanced stage disease (International Staging System (ISS) III: 66 17 
v 13%, Revised-ISS III: 34 v 5%, p<0.001). See Table 1. Since RI is one of the defining criteria for ISS 18 
stage (both ISS and R-ISS) and beta-2 microglobulin (β2M) is affected by renal function, we reviewed 19 
the other staging criteria to determine whether RI alone was the reason for increased stage in this 20 
group. The R-ISS components of high-risk FISH and LDH were compared, showing that 57% with RI 21 
versus 44% with no RI had these high-risk changes (p=0.01). Patients with RI had a higher LDH (205 22 
U/L, 164-261) compared with no RI (186 U/L, 152- 234) (p<0.001) which is likely to reflect myeloma 23 
cell proliferation. High-risk FISH abnormalities were present in 31% of patients with RI, and 24% with 24 
no RI (p=0.07).  25 
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Patients with RI had a worse performance status (ECOG 2-4: 30 v 18%, p<0.001) and more co-1 
morbidities: more patients with RI had diabetes (15 v 9%, p=0.005), cardiac disease (15 v 8%, 2 
p<0.001) and abnormal liver function tests (2.6 v 0.7%, p=0.01). There was no difference in the 3 
prevalence of pulmonary disease or peripheral neuropathy between the two groups (See Table 1). 4 
In disease manifestations other than RI defining MM activity, hypercalcaemia (10 v 4%, p=0.001) and 5 
anaemia (43 v 16%, p<0.001) were both more common in patients with RI; however fewer patients 6 
with RI had bone lesions (53 v 67%, p<0.001). 7 
Treatment and response 8 
The time from diagnosis to commencement of induction therapy was shorter in patients with RI 9 
(median 15 days; IQR 13 to 18 days, 90
th
 centile 60 days) compared with no RI (25 days; 22-27, 10 
p<0.001). Bortezomib-based therapy was most commonly used for induction in all patients, however 11 
it was given to fewer patients with RI (80% v 88%, p=0.002, see Table 2). Carfilzomib-based therapy 12 
was used in 2.2% of patients with RI and 0.5% of non-RI patients. Overall the percentage of patients 13 
who received a PI of either bortezomib or carfilzomib was still lower in patients with RI (82.5%) 14 
compared with non-RI (88.3%) (p=0.013). Although carfilzomib is not approved for first line 15 
treatment of MM in our jurisdiction, a clinical trial on carfilzomib/dexamethasone was in progress 16 
specifically for RI patients during the period of data collection. Contrary to the understanding that 17 
PIs are particularly effective in MM patients with RI, there was no obvious factor identified for the 18 
lower proportion of RI patients receiving a PI as first line therapy compared with other treatments. 19 
We investigated the possibility that parenteral treatment of bortezomib may be less favoured in 20 
older patients compared with oral treatment, but this was not the case as a greater proportion of 21 
patients with RI over 70 years compared with no RI received bortezomib [75% (145/193) v 69% 22 
(120/173)], with the reverse finding in patients 70 years or under [86% (143/166) v 94% (448/475)]. 23 
Response rates (≥PR) to bortezomib in both groups were similar (≥PR rate 81% in RI v 84% in no RI, 24 
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p=0.28), and there was also no statistically significant difference in response to thalidomide-based 1 
therapy between groups (≥PR: RI 48% v no RI 67%, p=0.12). 2 
Fewer TE patients (defined in Methods) with RI received ASCT (62 v 78%, p<0.001) and ASCTs were 3 
performed at all levels of renal function including in patients with severe RI (eGFR <30 mL/min). The 4 
proportion of patients transplanted at each eGFR level was: eGFR 30-59 mL/min (63%), eGFR 15-30 5 
mL/min (58%) and eGFR <15 mL/min (61%). Standard dose melphalan (200mg/m
2
) was given for 6 
ASCT conditioning in 72 v 93% of patients with RI v no RI, and lower dose melphalan (140mg/m
2
) in 7 
27 v 5% of RI v no RI (Table 2). Among patients who were <70 years and had >1 year follow-up, those 8 
who received ASCT compared with those who did not receive ASCT, were younger (59.8 yrs vs 65.0 9 
yrs, p<0.001), had better performance status, a higher median eGFR (81 v 68 ml/min; p<0.001); but 10 
there was no significant difference in R-ISS categories (Supplementary data; Table 1).  11 
 12 
Although the age of 70 is commonly accepted within our jurisdiction as a threshold for transplant 13 
eligibility, we specifically reviewed the age group 65-70 years to determine whether patients in this 14 
group closest to the threshold were less likely to receive an ASCT if they had RI. While for both 15 
patients with and without RI, a lower proportion of older patients between 65 and 70 years were 16 
transplanted compared to patients under 65, the difference appeared to be more pronounced in the 17 
RI group (RI: 44 v 71%; no RI: 61 v 85%).  18 
Of 383 patients with RI at diagnosis, 18 were dialysed close to diagnosis, however two received 19 
dialysis for medical problems unrelated to myeloma. Of the remaining 16 patients, 94% (15/16) had 20 
eGFR< 15 mL/min at diagnosis, and 88% (14/16) received bortezomib first-line chemotherapy, with 21 
≥PR of 75% (9/12). Only 38% (3/8) versus 64% (87/137) of dialysed versus non-dialysed patients with 22 
RI underwent ASCT (p=0.14), however, there was no statistically significant difference in treatment, 23 
response, OS or PFS between groups (p≥0.06), which may be due to lack of power given the low 24 
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numbers. Of the dialysed patients, 7/16 (44%) became dialysis independent within three months of 1 
commencement. 2 
Plasma exchange was administered in 1.0% of patients with RI versus 1.7% in no RI (p=0.36). 3 
Progression-free and overall survival 4 
Median patient follow-up was 19 months. PFS and OS were reduced in patients with RI: median PFS 5 
was 25 versus 33 months (p<0.001), and median OS 47 months for RI, versus not reached; p<0.001 6 
(Table 2). For patients with RI, 75% were alive at 23 (18-27) months versus 38 (35-43) months for no 7 
RI (Figure 2). After adjustment for age, the hazard ratios (HR) for OS and PFS were 0.62 (95% CI 0.47-8 
0.81, p<0.001) and 0.74 (95% CI 0.61-0.91, p=0.004), respectively. After adjustment for other co-9 
morbidities – moderate to severe cardiac disease and ECOG performance status - in addition to age, 10 
the hazard ratios (HR) for OS and PFS were 0.72 (95% CI 0.52-0.99, p=0.045) and 0.80 (95% CI 0.63-11 
1.03, p=0.087), respectively. 12 
 13 
PFS and OS were compared across all stages of chronic kidney disease in Figure 2C and D indicating 14 
an increasing trend in survival time with better renal function. 15 
In patients with RI receiving bortezomib versus thalidomide-based first line chemotherapy (n=285 v 16 
32, those receiving both [n=3] were excluded) there was no difference in PFS (HR 0.78, 95%CI 0.48-17 
1.27, p=0.32) or OS (HR 0.89, 95%CI 0.49-1.61, p= 0.70). 18 
TE patients with RI who received ASCT had a longer OS (HR 0.41, 95%CI 0.19-0.90, p=0.03) and PFS 19 
(HR 0.54, 95% CI 0.32-0.93, p=0.03) compared with those who did not receive an ASCT (Figure 3).  20 
In ASCT recipients, there was no difference in PFS (HR 0.97, 95%CI 0.62-1.50, p=0.87) or OS (HR 0.82, 21 
95%CI 0.41-1.62, p=0.57) between patients with and without RI (Figure 4).  22 
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Patients with RI who received melphalan 200mg/m
2
 had a shorter median PFS than those who 1 
received 140mg/m
2
 (31 months v not reached, p=0.05; HR 0.43, CI 0.18-1.04, p=0.06), however there 2 
was no significant difference in OS or response to therapy (≥PR) between groups. 3 
Of 491 patients who were ≤70 years and received an ASCT, only 201 patients had data available on 4 
maintenance therapy. Of these patients 151/201 (75.1%) received thalidomide, the only agent 5 
approved for maintenance in our jurisdiction: 93 (46.2%) received thalidomide alone, 58 (28.9%) 6 
received thalidomide plus prednisolone, 5(2.5%) received prednisolone alone. Other maintenance 7 
therapies including bortezomib, lenalidomide, panobinostat were administered in the remaining 45 8 
patients, of which the majority (33/45[73%] or 33/201[16%] of the total cohort with maintenance 9 
data) was administered in clinical trials.  10 
Overall, 119 patients have died in the RI group (31%) and 118 patients in no-RI (17%). There was no 11 
significant difference in the median number of chemotherapy regimens administered prior to death. 12 
As diabetes is the most important cause  of RI in the Australian population
15
, we evaluated the 13 
possible effect of diabetes requiring treatment on myeloma outcome. We found no impact on PFS, 14 
OS, or response to first-line therapy (p≥0.8). While a larger proportion of patients with RI had 15 
diabetes than no RI (Table 1), in patients with RI, there was no significant difference in outcome 16 
between those with and without diabetes [≥PR 80.5% v 80.6%, p=0.99; PFS 25.0 (CI 19.5 – 34.4) v 17 
24.5 (20.2-28.5) months, p=0.89; OS 38.7 (30.2 – not reached) v. 47.9 (43.4-57.8) months, p=0.80]. In 18 
the Australian community the two other major causes of renal failure are glomerulonephritis and 19 
hypertension, for which current data in our registry do not enable an accurate assessment of their 20 
impact. 21 
 22 
  23 
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Discussion 1 
Key findings 2 
In our analysis of 1069 newly diagnosed MM patients from the ANZ MRDR, we found 36% had RI at 3 
diagnosis and this was associated with older age, presence of co-morbidities, worse performance 4 
status and higher-risk disease. Bortezomib-based therapy was the most common first-line treatment 5 
in RI, although this was used less frequently compared with those without RI, despite similar 6 
response rates. Patients with RI had a shorter OS and PFS compared with patients without RI after 7 
adjusting for age. Patients with RI were less likely to receive an ASCT; however those with RI who 8 
were transplanted had a longer PFS and OS than those who were not. In addition, OS and PFS were 9 
similar in those who received ASCT irrespective of the presence of RI.  10 
It is clear from previous studies that in the overall MM population, PFS and OS are superior for TE 11 
compared to NTE patients
16
. In our study, the improved PFS and OS for patients with no RI compared 12 
with RI remained significant after adjustment for age. However, as age, co-morbidities and 13 
performance status all constitute important eligibility criteria for ASCT, it is not surprising that when 14 
PFS and OS were adjusted for all these factors, the differences between RI and no RI became less 15 
pronounced, as this adjustment would mitigate the impact of ASCT on prognosis.  16 
In clinical trials of novel drugs or regimens in MM, patients with RI are often excluded, which limits 17 
our understanding of their response to treatment and outcomes. This cohort is from a binational 18 
registry of over 1250 myeloma patients with eGFR available from 85% of patients, providing the 19 
opportunity for assessment of the incidence, underlying factors, treatment and outcomes in newly 20 
diagnosed MM with RI in a large “real world” population. 21 
Comparison with other studies 22 
We show that patients with RI represented a third of newly diagnosed MM in the MRDR and that RI 23 
is associated with a poor prognosis
17-19
, consistent with other findings
6, 20, 21
. MM patients with RI 24 
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were older, had a higher prevalence of advanced stage disease and higher LDH (correlated with 1 
myeloma cell proliferation, despite a lower prevalence of bone lesions), and shorter PFS and OS.  2 
Since it is clear that PI have particular effectiveness in RI in MM,
22
 it is of interest to note that fewer 3 
RI patients in this population received them compared to the cohort without RI. We investigated the 4 
possibility that age may be a factor favouring oral immunomodulator therapy in the older age group 5 
but this was not the case. It is also possible that the RI was considered by the treating doctor not to 6 
be due to MM in some of these patients, and hence a PI was not utilised in the initial treatment.  7 
Furthermore, there was no difference in the best clinical response between patients with RI versus 8 
no RI either in bortezomib-based or thalidomide-based treatment. In addition, for patients with 9 
RI receiving bortezomib versus thalidomide-based first line chemotherapy, there was no significant 10 
difference in PFS or OS (p>0.32), however the number of patients on thalidomide was low (n=32). 11 
Before the era of ‘novel agents’, RI in MM was associated with poor prognosis.
23-25
 Since then, 12 
evidence suggests that the reversal of RI may be associated with an improvement in prognosis
26-28
 13 
with novel agents playing a significant role.
10, 29
 However, as long-term follow-up data on renal 14 
response is not routinely collected on all MRDR patients, it was not possible to ascertain the 15 
difference in efficacy of each treatment in reversing RI. Given the importance of prompt initiation of 16 
treatment in patients with RI, and the established link between reversal of RI and prognosis, it is 17 
pleasing to see that the median time from diagnosis to treatment for RI (median 15 days, IQR 13-18) 18 
is significantly lower though still considered clinically suboptimal; it is of even greater concern that 19 
10% of RI patients started treatment after 60 days. 20 
This study has shown that ASCT is commonly performed in Australian and New Zealand patients with 21 
RI and at all levels of renal function, however the rate of ASCT is still lower in RI than in patients with 22 
normal renal function  (62% vs 78%, p<0.001). This was particularly the case in patients close to the 23 
age threshold of transplant eligibility of 65-70 years, where the difference was 44% vs 71% for RI vs 24 
no RI. A long-standing concern is the reported increased morbidity and mortality of ASCT in patients 25 
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with RI, attributed to the possible accumulation of melphalan, the most common conditioning agent 1 
which requires renal clearance. The evidence for ASCT in MM patients with RI is heterogeneous. A 2 
recent CIBMTR review
8
 showed that for patients who received ASCT no difference was seen in PFS or 3 
OS for patients with different levels of renal function. The study did not include a comparison with 4 
non-transplanted patients. The same CIBMTR report did not show any difference in outcomes 5 
between full-dose (200 mg/m
2
) and reduced-dose (140 mg/m
2
) conditioning, except in a group with 6 
eGFR 30-59 mL/min, in whom a higher dose of melphalan (200 mg/m
2
) was associated with 7 
improved PFS. In contrast, a clinical trial of ASCT in patients with eGFR <30 ml/min showed that only 8 
reduced-dose melphalan conditioning of 140 mg/m
2
 led to an improved PFS compared with 9 
historical controls with normal renal function.
30
 10 
Our study showed that patients with RI who underwent ASCT were more likely to have a longer PFS 11 
and OS than those who did not receive ASCT. Furthermore, in patients who underwent ASCT, there 12 
was no difference in PFS and OS between patients with and without RI. These results support the 13 
use of ASCT in TE patients with RI and with appropriate performance status. However, we found that 14 
a significantly lower proportion of patients with RI received ASCT compared with those with no RI. 15 
The worse ECOG status of patients with RI (Table 1) may have accounted for TE patients with RI not 16 
receiving ASCT. In addition, in our cohort, a significantly higher percentage of patients with RI v no RI 17 
(27 v 5%) are administered the lower melphalan dose (140 mg/m
2
). Patients with RI who received 18 
melphalan 200mg/m
2
 had a shorter PFS than those on 140 mg/m
2
 (31 months v not reached, p=0.05; 19 
HR 0.43, CI 0.18-1.04, p=0.06), however there was no significant difference in OS or response to 20 
therapy (≥PR) between groups. Thus, as in the CIBMTR study, we saw no clear advantage for either 21 
of the two doses of melphalan conditioning.  22 
At the time of data collection, the only funded maintenance treatment available in our jurisdiction 23 
was thalidomide. Of patients ≤70 years who received an ASCT and had data on maintenance therapy 24 
(n=201), three-quarters received thalidomide, and the remainder were given numerous therapies 25 
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including small numbers treated with bortezomib, lenalidomide and panobinostat maintenance, 1 
predominantly on clinical trials. Due to the lack of maintenance therapy data in over half the 2 
transplanted patients and the heterogeneity of regimens, we cannot compare strategies and their 3 
impact on disease; rather we can present an overall view of maintenance therapy use in our 4 
community.   5 
Of 383 patients with RI, 16 were dialysed for reasons related to their myeloma disease. There was no 6 
significant difference in treatment, response, OS or PFS between dialysed versus non-dialysed 7 
groups (p≥0.06), which may be due to lack of power with the low numbers. However, it was pleasing 8 
to see that of the dialysed patients, 7/16 (44%) became independent of dialysis within 3 months of 9 
commencement.  10 
While we are not able to determine the cause of shortened OS definitively from the registry data for 11 
patients with RI; potential contributing factors include suboptimal use of PI and ASCT. There was no 12 
evidence of increased treatment-related mortality: cause of death was disease-related in 87% of 13 
patients with RI and 85% without RI. It is likely that reduced efficacy of treatment leading to earlier 14 
relapse in patients with RI (as seen in the shorter PFS) is the main cause of the reduced OS rather 15 
than treatment-related or other causes of mortality. 16 
Strengths and limitations 17 
The use of a binational clinical registry with 5 years of prospective data collection from 23 18 
institutions representing metropolitan and regional healthcare underlies the strength and 19 
generalisability of our findings. Limitations include the observational nature of the study, missing 20 
data on baseline renal function in 15% of patients, the lack of data on the precise cause of renal 21 
impairment (MM or non-MM related) and the absence of follow-up data for renal function to assess 22 
renal outcomes. 23 
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Conclusion 1 
In summary, these findings confirm the higher risk of MM in the presence of RI at diagnosis, with a 2 
shortened PFS and OS. While patient characteristics such as more advanced age, poorer ECOG status 3 
and higher tumour burden may be important factors, our findings also reveal possible treatment-4 
related factors such as delay in commencing treatment, with 10% of RI patients starting treatment 5 
after 60 days, as well as a suboptimal utilisation of bortezomib and ASCT as possible contributors. 6 
Our findings clearly support the use of ASCT in MM patients with RI to achieve better OS and PFS, 7 
with no advantage of either full-dose or reduced-dose melphalan conditioning. Although follow-up 8 
data on renal response was not available, just over 40% of patients who were dialysed due to MM 9 
became dialysis-independent within three months of treatment. Given our understanding of the 10 
importance of consolidation and maintenance in both TE and non-TE patients with normal renal 11 
function, future review of these additional strategies will provide useful information. Furthermore, 12 
the introduction of induction therapies such as the newer PI, immunomodulatory drugs and 13 
monoclonal antibodies will also likely change the outlook for this group of high-risk patients.  14 
Clinical practice points 15 
• Patients diagnosed with MM frequently have RI (36% of MM in our cohort) which is known 16 
to be associated with adverse outcomes.  17 
• In a large real world MM cohort, this study confirms the adverse prognostic impact of RI on 18 
MM patients, and describes the factors contributing to adverse outcomes.  19 
• Treatment-related factors that may have contributed to adverse outcomes are a prolonged 20 
time to induction therapy, and suboptimal utilisation of bortezomib and ASCT.  21 
• Over 40% of patients who were dialysed due to MM at diagnosis became dialysis-22 
independent within three months of treatment.  23 
• Results suggest that the increased use of ASCT in appropriate patients, PIs for induction, and 24 
a reduction in delays to treatment could lead to improved prognosis in MM with RI.  25 
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Table 1. Patient characteristics at diagnosis (eGFR <60 versus eGFR ≥60 mL/min/1.73m
2
) 1 
 2 
 3 
*High risk group= patients with high risk FISH (abnormalities: del17p, t(4;14), t(14;16), amp(1q21) or high 4 
LDH ≥300, †FISH abnormaliAes: del17p, t(4;14), t(14;16), amp1q21, ‡ Upper limit of normal for LDH=250 U/L, 5 
**diabetes requiring medication.  6 
 7 
  8 
 eGFR < 60 eGFR ≥ 60 P value 
N 383 686  
Serum creatinine, µmol/L, median 143.0 (113.0, 229.0) 76.0 (67.0, 88.0) <0.001 
eGFR 39.0 (21.0, 51.0) 83.0 (71.0, 90.0) <0.001 
Paraprotein type    
     IgG 202/379 (53.3%) 415/679 (61.1%)  
     IgA 70/379 (18.5%) 142/679 (20.9%)  
     IgM 2/379 (0.5%) 3/679 (0.4%)  
     IgD 6/379 (1.6%) 3/679 (0.4%)  
     Light chain Kappa 61/379 (16.1%) 68/679 (10.0%)  
     Light chain Lambda 35/379 (9.2%) 31/679 (4.6%)  
     Non-secretory MM 2/379 (0.5%) 12/679 (1.8%)  
     Biclonal 1/379 (0.3%) 5/679 (0.7%)  
Light chain isotype   0.85 
     Kappa 173/275 (62.9%) 349/549 (63.6%)  
     Lambda 102/275 (37.1%) 200/549 (36.4%)  
Age (years), median (IQR) 71.6 (63.2, 79.1) 64.5 (56.5, 71.0) <0.001 
Age > 70 years 212/383 (55.4%) 188/686 (27.4%) <0.001 
Gender (Male) 233/383 (60.8%) 421/685 (61.5%) 0.84 
ISS = 3  191/289 (66.1%) 64/513 (12.5%) <0.001 
R-ISS = 3 62/181 (34.3%) 18/351 (5.1%) <0.001 
β2 microglobulin, median (IQR), mg/L 6.9 (4.6, 12.2) 3.0 (2.3, 4.1) <0.001 
Albumin, g/L 33 (28,37) 35 (31, 40) <0.001 
High-risk group (FISH or LDH)* 79/138 (57.2%) 126/284 (44.4%) 0.01 
High-risk FISH † 50/160 (31.3%) 82/346 (23.7%) 0.07 
LDH (U/L), median (IQR)‡ 205.0 (164.0, 261.0) 186.0 (152.0, 234.0) <0.001 
LDH ≥?300 32/234 (13.7%) 51/485 (10.5%) 0.21 
ECOG performance status = 2-4 74/249 (29.7%) 84/467 (18.0%) <0.001 
Diabetes** 56/383 (14.6%) 62/686 (9.0%) 0.005 
Moderate to severe cardiac disease   59/383 (15.4%) 57/686 (8.3%) <0.001 
Moderate to severe pulmonary disease   25/383 (6.5%) 31/686 (4.5%) 0.16 
Abnormal liver function tests  10/383 (2.6%) 5/686 (0.7%) 0.01 
Peripheral neuropathy 14/383 (3.7%) 14/686 (2.0%) 0.11 
Hypercalcaemia 40/383 (10.4%) 30/686 (4.4%) <0.001 
Anaemia 163/383 (42.6%) 108/686 (15.7%) <0.001 
Bone lesions 202/383 (52.7%) 456/686 (66.5%) <0.001 
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Table 2. Treatment, response and survival (eGFR<60 versus eGFR≥60 mL/min/1.73 m
2
) 1 
 eGFR < 60 eGFR ≥ 60 P value 
N 383 686  
Time from Dx to Rx (days), median (IQR) 15.0 (13.0, 18.0) 25.0 (22.0, 27.0) <0.001 
Time from Dx to ASCT (days), median (IQR) 199 (155-279) 195 (165-249) 0.55 
Overall best clinical response (≥ PR*)  219/272 (80.5%) 457/547 (83.5%) 0.28 
Bortezomib-based therapy 288/359 (80.2%) 568/648 (87.7%) 0.002 
BCR in bortezomib-based therapy (≥ PR)‡  194/228 (85.1%) 423/492 (86.0%) 0.75 
Thalidomide-based therapy 35/359 (9.7%) 54/648 (8.3%) 0.45 
BCR in thalidomide-based therapy (≥ PR) 11/23 (47.8%) 31/46 (67.4%) 0.12 
Lenalidomide-based therapy 11/359 (3.1%) 16/648 (2.5%) 0.58 
BCR in lenalidomide-based therapy (≥ PR) 2/5 (40.0%) 7/9 (77.8%) 0.16 
Carfilzomib-based therapy 8/359 (2.2%) 4/648 (0.5%) 0.02 
BCR in carfilzomib-based therapy (≥ PR) 6/6 (100%) 1/1 (100%)  
Bortezomib or carfilzomib-based therapy 296/359 (82.5%) 571/648 (88.1%) 0.01 
ASCT performed & age ≤ 70 years† 90/145 (62.1%) 335/429 (78.1%) <0.001 
ASCT conditioning    <0.001 
     Melphalan 200mg/m
2
 70/97 (72.2%) 341/365 (93.4%)  
     Melphalan 140mg/m
2
 26/97 (26.8%) 17/365 (4.7%)  
     Other** 1/97 (1.0%) 7/365 (1.9%)  
Plasma exchange therapy used  4/383 (1.0%) 12/686 (1.7%) 0.36 
PFS (m), median (95% CI) 24.9 (21.3-28.5) 33.1 (29.7-36.4) <0.001 
Overall survival (m), median (95% CI) 47.2 (41.9-50.4) 67.1 (58.8+) <0.001 
Cause of death: disease-related (MM) 61/70 (87%) 69/81 (85%) 0.73 
Deceased patients  119 (31.1%) 118 (17.2%)  
No. of chemotherapy regimens administered 
in deceased patients (median, IQR) 
1.5 (1,3) 2 (1, 3) 0.08 
 2 
All chemotherapy drug and response variables relate to first-line therapy, *≥PR= partial response 3 
or beEer to therapy, ‡BCR=best clinical response, †paAents with diagnosis date ≥ 1 year prior to 4 
data extract and with follow-up data (age ≤ 70 is used as this is consensus practice for transplant 5 
eligibility in Australia and New Zealand and only ten patients aged >70 years had ASCT). 6 
**Other=alternative doses of melphalan or other conditioning used. 7 
 8 
  9 
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 1 
FIGURES – the figure title is above with the legend below if relevant  2 
 3 
 4 
 5 
FIGURE 1. PATIENT FLOW CHART 6 
 7 
MGUS=MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE, 8 
SMM=SMOULDERING MULTIPLE MYELOMA, PCL=PLASMA CELL LEUKAEMIA 9 
 10 
 11 
 12 
 13 
 14 
FIGURE 2. PROGRESSION-FREE AND OVERALL SURVIVAL IN MULTIPLE MYELOMA BY RENAL 15 
FUNCTION AT DIAGNOSIS: A AND B COMPARE EGFR<60 VERSUS ≥60 ML/MIN; C AND D 16 
COMPARE EGFR CATEGORIES FOR CHRONIC KIDNEY DISEASE  17 
 18 
 19 
 20 
 21 
 22 
FIGURE 3. PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE 23 
MYELOMA AND RENAL IMPAIRMENT (EGFR<60 ML/MIN) AT DIAGNOSIS, IN PATIENTS WHO 24 
HAD AND DID NOT HAVE AUTOLOGOUS STEM CELL TRANSPLANT 25 
 26 
 27 
 28 
 29 
 30 
FIGURE 4. PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE 31 
MYELOMA WHO HAD AN AUTOLOGOUS STEM CELL TRANSPLANT, COMPARING PATIENTS 32 
WITH EGFR<60 VERSUS ≥60 ML/MIN AT DIAGNOSIS 33 
 34 
 35 
 36 
 37 
 38 
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 1 
Supplementary Data 2 
 3 
Table I 4 
 5 
Characteristics of patients <70 years of age who were diagnosed with MM >1 year prior to data 6 
extraction and have follow up data (defined as TE in this study), according to ASCT versus No ASCT 7 
Factor Level No ASCT ASCT p-value 
N 
 
168 491 
 Age at diagnosis, median 
(IQR) 
 
65.0 (58.7, 68.1) 59.8 (53.0, 64.4) <0.001 
Gender (male) 
 
100/168 (59.5%) 314/490 (64.1%) 0.29 
ISS 1 26/110 (23.6%) 132/353 (37.4%) 0.029 
 
2 50/110 (45.5%) 131/353 (37.1%) 
 3 34/110 (30.9%) 90/353 (25.5%) 
 R-ISS 1 4/80 (5.0%) 26/229 (11.4%) 0.12 
 
2 61/80 (76.3%) 175/229 (76.4%) 
 
 
3 15/80 (18.8%) 28/229 (12.2%) 
 ECOG Performance Status 0 36/109 (33.0%) 138/330 (41.8%) <0.001 
 
1 42/109 (38.5%) 146/330 (44.2%) 
 
 
2 19/109 (17.4%) 36/330 (10.9%) 
 3 8/109 (7.3%) 10/330 (3.0%) 
 4 4/109 (3.7%) 0/330 (0.0%) 
 eGFR, median (IQR) 
 
68 (45, 81) 81 (64, 90) <0.001 
 8 
Although more complete data were available for ISS than R-ISS, and there appeared to be a 9 
significantly higher number of patients in lower ISS stages within the ASCT group, R-ISS is considered 10 
to be more informative given the greater reliance of ISS on beta-2 microglobulin (being one of 2 11 
parameters) which can be affected by eGFR. The absence of a difference in R-ISS indicates no 12 
significant difference in MM stage in potential TE patients who received or did not receive an ASCT. 13 
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